The goal of this program is to improve the management of diffuse large B-cell lymphoma (DLBCL). After hearing and assimilating this program, the clinician will be better able to:Compare the differences among chimeric antigen receptor T-cell (CAR-T) products used in DLBCL.Contrast toxicity among CAR-T producs.Explain evidence assessing effectiveness of epcoritamab in management of DLBCL.
- Provider:Lippincott Continuing Medical Education Institute, Inc.
- Activity Link: https://www.audio-digest.org/Specialties/Oncology
- Start Date: 2023-09-12 05:00:00
- End Date: 2023-09-12 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.25 hours
- MOC Credit Details: ABIM - 1.25 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Yes
- Measured Outcome: Learner Competence, Learner Knowledge, Learner Performance
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Medical Oncology
Subscribe
Login
0 Comments
Oldest